Oxygen Double Bonded And Nitrogen Bonded Directly To The Same Carbon Patents (Class 536/53)
  • NOVEL CYANINE COMPOUND FOR LABELING BIOMOLECULE AND PREPARATION METHOD THEREOF
    Publication number: 20120095187
    Abstract: Disclosed are a novel cyanine compound, represented by the following Formula 1, for labeling biomolecules, and a method for preparing the same. wherein R1, R2, R3, R4, B, m and n are defined as above.
    Type: Application
    Filed: April 2, 2010
    Publication date: April 19, 2012
    Applicants: DKC CORPORATION, KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Dong Jin Kim, Young Soo Kim, Jong Joo Na, Jin Woo Park, Ki Won Kim
  • NOVEL SILANE COMPOUNDS HAVING A CYCLIC CARBON CHAIN INCLUDING AN ALKYNE FUNCTION FOR FUNCTIONALISING SOLID SUBSTRATES AND IMMOBILISING BIOLOGICAL MOLECULES ON SAID SUBSTRATES
    Publication number: 20120095203
    Abstract: The invention relates to a silane compound including a cycloalkyne functionality, to a method for functionalising a solid substrate, and to the solid substrate thus produced. The silane compound of the invention corresponds to the formula X-E-A-Z where X is a silyl group, E is an organic spacer group, A is a single bond or a —CONH—, —NHCO—, —OCH2CONH—, —NHCOCH2O—, —0— or —S— group, and Z is a cycloalkyne or heterocycloalkyne with at least 8 members. The invention is particularly suitable for use in the field of medicine.
    Type: Application
    Filed: March 16, 2010
    Publication date: April 19, 2012
    Applicant: Commissariat A L'Energie Atomique Et Aux Ene Alt
    Inventors: Aude Bernardin, Guillaume Delapierre, Antoine Hoang, Isabelle Texier-Nogues
  • Sugar chain asparagine derivatives, sugar chain asparagine, sugar chain and processes for producing these
    Patent number: 8158763
    Abstract: An asparagine-linked ?2,3-oligosaccharide having undeca- to hepta-saccharides, an asparagine-linked ?2,6-oligosaccharide having undeca- to hepta-saccharides and containing fluorine and an asparagine-linked oligosaccharide derivative containing at least one fucose in N-acetylglucosamine on the nonreducing terminal side of an asparagine-linked oligosaccharide wherein the asparagine has amino group protected with a lipophilic protective group, and a process for producing these compounds.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: April 17, 2012
    Assignees: Otsuka Chemical Co. Ltd.
    Inventors: Yasuhiro Kajihara, Kazuaki Kakehi, Kazuhiro Fukae
  • Polysaccharide-polypeptide conjugate
    Patent number: 8153135
    Abstract: Disclosed is a method of producing a polysaccharide-polypeptide conjugate by reacting a polysaccharide with a polypeptide which contains at least one free amino group, wherein a polysaccharide carrier comprising vicinal hydroxyl groups is oxidized under ring opening to create vicinal aldehyde groups and is reacted with one or more base-instable antigenic polypeptide(s) containing at least one free amino group, the polypeptide(s) being bound directly to the polysaccharide carrier via at least one azomethine bond.
    Type: Grant
    Filed: September 13, 2005
    Date of Patent: April 10, 2012
    Inventors: Hans Loibner, Helmut Eckert
  • Methods for altering surface characteristics of microspheres
    Patent number: 8153440
    Abstract: Various methods for altering surface characteristics of a microsphere are provided. One method includes coupling an enolic acid to the microsphere to modify the surface characteristics of the microsphere. The surface characteristics may include charge density and/or pKa. A reagent can be coupled to the microsphere via the enolic acid. The reagent may include a biomolecule. The modified surface characteristics may increase a stability of the reagent when the reagent is coupled to the microsphere. The modified surface characteristics may also improve performance of an assay carried out with the microsphere. Another embodiment relates to a microsphere that includes an enolic acid coupled to a polymer core of the microsphere such that the enolic acid modifies surface characteristics of the microsphere. A reagent can be coupled to the microsphere via the enolic acid.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: April 10, 2012
    Assignee: Luminex Corporation
    Inventors: Ananda G. Lugade, Kurt D. Hoffacker
  • NOVEL SALTS OF SITAGLIPTIN
    Publication number: 20120077760
    Abstract: The present invention relates to novel pharmaceutically acceptable salts of sitagliptin, to processes for their preparation and to pharmaceutical compositions containing them.
    Type: Application
    Filed: February 10, 2010
    Publication date: March 29, 2012
    Applicant: LEK Pharmaceuticals D.D.
    Inventors: Lovro Selic, Ivan Plantan
  • Process for producing water-soluble hyaluronic acid modification
    Patent number: 8143391
    Abstract: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction ratio of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction ratio as that of the conventionally known gel.
    Type: Grant
    Filed: September 7, 2005
    Date of Patent: March 27, 2012
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Kenji Yasugi, Teruo Nakamura, Tsuyoshi Shimoboji, Mika Sato
  • 6'-SIALYLLACTOSE SALTS AND PROCESS FOR THEIR SYNTHESIS AND FOR THE SYNTHESIS OF OTHER ALPHA-SIALYLOLIGOSACCHARIDES
    Publication number: 20120071441
    Abstract: The present invention relates to a process of synthesis of ?-sialyl oligosaccharides and in particular of 6?-sialyllactose and its salts comprising a step of coupling by Koenigs-Knorr reaction under conditions that allow its use on an industrial scale.
    Type: Application
    Filed: April 6, 2010
    Publication date: March 22, 2012
    Applicant: INALCO S.P.A.
    Inventors: Giancarlo Tamerlani, Ilaria Lombardi, Debora Bartalucci, Andrea Danesi, Liana Salsini, Marco Manoni, Giovanni Cipolletti
  • Synthetic polysaccharide antigens for immunological intervention in disease
    Patent number: 8129518
    Abstract: Provided are synthetic polysaccharide antigens (SPAs) with anti-inflammatory or inflammatory immunomodulatory properties, depending on their structure. Also provided are compositions comprising these SPAs, and methods of using these SPAs and compositions to either prevent or treat inflammatory pathologies, or diseases or conditions susceptible to treatment with inflammatory immunomodulators, by using appropriate SPAs.
    Type: Grant
    Filed: September 15, 2004
    Date of Patent: March 6, 2012
    Assignee: Eli Lilly and Company
    Inventors: Larry Chris Blaszczak, John Astor Cleveland, Jr., Kathleen Ann Taylor, Neil Thomas Blackburn, Angelika Regina Kraft, Charles Ellis Cohen
  • COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450
    Publication number: 20120053132
    Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
    Type: Application
    Filed: November 1, 2011
    Publication date: March 1, 2012
    Applicant: Sequoia Pharmaceuticals, Inc.
    Inventors: Michael Eissenstat, Dehui Duan
  • AMPHIPHILIC COMPOUNDS AND SELF-ASSEMBLING COMPOSITIONS MADE THEREFROM
    Publication number: 20120052042
    Abstract: The present disclosure relates to amphiphilic compounds, self assembling compositions formed from the amphiphilic compounds and methods of making such compositions.
    Type: Application
    Filed: February 22, 2010
    Publication date: March 1, 2012
    Inventors: Sébastien Ladet, Philippe Gravagna
  • Thiol-modified macromolecule derivatives and cross-linked materials thereof
    Patent number: 8124757
    Abstract: The disclosed is thiol-modified macromolecule derivatives having the general formula of (I) or (II), as well as the disulfide bond cross-linked materials and the thiol-reactive crosslinker cross-linked materials, wherein R1 and R2 are alkylene groups, substituted alkylene groups, aromatic groups or polyether groups and the like, respectively. R1 and R2 may have same or different chemical structure, and P is a residue of a macromolecule with side carboxyl group. The thiol-modified macromolecule derivative has a molecular weight of from 1000 to 5,000,000. The thiol-modified macromolecule derivative having the general formula of (I) or (II) of the present invention has a side chain with flexible chemical structure and adjustable properties, and has a number of advantages, such as mild reaction condition, high production yield, high degree of modifying, and the controllable modifying degree and so on.
    Type: Grant
    Filed: September 29, 2007
    Date of Patent: February 28, 2012
    Assignee: Bioregen Biomedical (Changzhou) Co., Ltd.
    Inventor: Chan Song
  • OLIGOSACCHARIDE INGREDIENT
    Publication number: 20120045566
    Abstract: An oligosaccharide ingredient comprising glycosylated amino acids and peptides of the general formula RnSacm where R is an amino acid residue, Sac is a monosaccharide selected from the group comprising N-acetyl-neuraminic acid, N-acetyl galactosamine and galactose, n has a value between 1 and 10 with the proviso that if n has the value 1 R is a threonine residue or a serine residue and if n has a value between 2 and 10 the peptide contains at least one threonine or serine residue, m has a value between 2 and 4 and at least 20 mol % of the ingredient is N-acetyl-neuraminic acid.
    Type: Application
    Filed: March 4, 2009
    Publication date: February 23, 2012
    Applicant: NESTEC S.A.
    Inventors: Norbert Sprenger, Rafael Berrocal, Marie-Claire Fichot
  • MEDICAL DEVICES HAVING ACTIVATED SURFACES
    Publication number: 20120046737
    Abstract: Implantable biocompatible polymeric medical devices include a substrate with an acid or base-modified surface which is subsequently modified to include click reactive members.
    Type: Application
    Filed: February 19, 2010
    Publication date: February 23, 2012
    Inventors: Nadya Belcheva, Ferass Abuzaina, Amin Elachchabi, Mbiya Kapiamba, Ahmad Robert Hadba
  • POLYSACCHARIDE DERIVATIVE AND HYDROGEL THEREOF
    Publication number: 20120035128
    Abstract: Disclosed are a polysaccharide derivative obtained by substituting some of the carboxyl groups of a carboxy polysaccharide with —NH—X—CO—Y—Z; and a hydrogel thereof. Here, X is a C1-10 hydrocarbon group, Y is a polyalkylene oxide having oxygen atoms at both ends, and Z is a C1-24 hydrocarbon group or —CO—R2, with R2 being a C1-23 hydrocarbon group. The hydrogel has excellent viscoelasticity and can be injected into a predetermined location with an injection device such as a syringe, and thus can be advantageously used as a medical gel or an adhesion barrier.
    Type: Application
    Filed: April 19, 2010
    Publication date: February 9, 2012
    Applicant: TEIJIN LIMITED
    Inventors: Hiroaki Kaneko, Masaya Ito
  • DETECTION OF TRICHOMONAS AND CANDIDA
    Publication number: 20120034637
    Abstract: The invention relates to a method and a kit for the detection of Trichomonas infection by detecting N-acetyl-?-D-hexosaminidase activity. The invention also relates to a method and a kit for selective detection of presence of Trichomonas or Candida infection.
    Type: Application
    Filed: January 27, 2010
    Publication date: February 9, 2012
    Inventors: Zeyu Wang, Hongyun Yang, Guangyu Fu, Xuewei Wu, Chaojie Feng, Yang Yang, Jingjing Yang, Yuanyuan Xie, Yehuan Zheng, Guilin Li, Fan Yang
  • FIBCD1 FOR THE PREVENTION AND TREATMENT OF DISEASES
    Publication number: 20120020958
    Abstract: The present invention relates to methods and compositions for the treatment and/or prevention of diseases such as allergic diseases and inflammatory bowel diseases comprising one or more FIBCD1 binding molecules or pharmaceutically acceptable salts, esters, and amides thereof and optionally one or more non-FIBCD1 binding molecules or pharmaceutically acceptable salts, esters, and amides thereof; as well as the use of such pharmaceutical composition for the prevention and/or treatment of diseases such as allergic diseases and inflammatory bowel diseases. FIBCD1 is herein defined as either a transmembrane receptor, the corresponding DNA or the corresponding mRNA as defined by SEQ ID No. 1, 2 and 3 as well as homologous thereof.
    Type: Application
    Filed: December 30, 2008
    Publication date: January 26, 2012
    Applicant: Dansk Universitet
    Inventors: Uffe Holmskov, Anders Schlosser
  • Bismuth hyaluronate, the preparation method and the use thereof
    Patent number: 8093374
    Abstract: The present invention discloses a bismuth hyaluronate, characterized in that the bismuth content is from 0.5% to 40%, and the glucuronate content is from 20% to 45%, based on dry weight. Also provided is a method for the preparation of said bismuth hyaluronate comprising reaction of a soluble hyaluronate salt with a bismuth salt in a basic aqueous solution, followed by steps of precipitation, filtration, desalting, dehydrating and drying to obtain the product. Further disclosed is the use of the bismuth hyaluronate in the manufacture of a medicament or health foods for preventing and treating gastrointestinal disorders, in particular ulcerous disorders of the GI tract. It has been proven in animal experiments to show a better therapeutic effect than products of the same type.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: January 10, 2012
    Inventors: Peixue Ling, Yanli He, Jianying Chen, Jie Liu, Tianmin Zhang, Xueping Guo, Yan Jin
  • COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT CFTR CELLULAR PROCESSING
    Publication number: 20120004405
    Abstract: The present invention relates to a compound which is characterized by the formula (I) or a pharmaceutically acceptable salt, solvate, hydrate thereof, wherein the ring systems A and B are independently selected from a monosaccharide, aryl (preferably phenyl), a heteroaryl or cycloalkyl (preferably cyclohexan), preferably with all substituents in equatorial configurations; R1 is independently selected from alkyl (preferably C1 to C6), a substituted or unsubstituted phenyl, preferably CH3; R2 is H, alkyl (preferably C1 to C6), a carbohydrate in a glycosidic ?-linkage, preferably H; R3, R4, R5, and R6 are independently selected from H, (OH) hydroxy, alkyl preferably C1 to C6, alkoxy (preferably C1 to C6), amino, alkylamino (preferably C1 to C6), halogen, benzylamino, or benzoylamino; X is O, NH, alkylamino (NR), CO, S; and Y is O, NH, alkylamino (NR), CO, S.
    Type: Application
    Filed: December 14, 2009
    Publication date: January 5, 2012
    Inventor: Peter Prehm
  • Hyaluronic acid-methotrexate conjugate
    Patent number: 8088916
    Abstract: An object of the present invention is to provide a hyaluronic acid-methotrexate conjugate useful as a therapeutic drug for joint diseases. There is provided a hyaluronic acid-methotrexate conjugate useful as a therapeutic drug for joint diseases, wherein methotrexate is conjugated with a carboxyl group of hyaluronic acid through a linker containing a peptide chain consisting of 1 to 8 amino acids.
    Type: Grant
    Filed: March 4, 2005
    Date of Patent: January 3, 2012
    Assignee: Denki Kagaku Kogyo Kabushiki Kaisha
    Inventors: Hitoshi Ikeya, Tadashi Morikawa, Koichi Takahashi, Tatsuya Tamura, Akira Okamachi, Takenori Ishizawa, Haruhiko Sato, Yoshinobu Higuchi
  • Process for the Purification of Antibodies Using Affinity Resins Comprising Specific Ligands
    Publication number: 20110319592
    Abstract: The present invention relates to a novel process for the purification of antibodies, e.g. monoclonal antibodies. The process utilizes an affinity resin comprising a solid phase material having immobilized thereto one or more low-molecular weight synthetic ligands. The affinity resins enable the separation of antibodies from even closely related proteins.
    Type: Application
    Filed: November 13, 2009
    Publication date: December 29, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Phaedria Marie St. Hilaire, Anders Laerke Nielsen
  • INHIBITORS OF F18+ E COLI BINDING
    Publication number: 20110306574
    Abstract: The present invention relates to blood group A/B/H determinant on Type 1 Core glycosphingolipids chains as recognition point for the FedF protein of F18-fimbriated Enterotoxigenic and verotoxinogenic Escherichia coli and the use of compounds comprising such determinants for the treatment of F18? E. coli infections in pigs and in screening methods.
    Type: Application
    Filed: September 30, 2009
    Publication date: December 15, 2011
    Applicant: GHENT UNIVERSITY
    Inventors: Annelies Coddens, Eric Cox, Susann Eva Teneberg
  • 4-ISOPROPYLPHENYL GLUCITOL COMPOUNDS AS SGLT1 INHIBITORS
    Publication number: 20110306759
    Abstract: The present invention provides 4-isopropylphenyl glucitol compounds which have no tendency to accumulate in the body and which inhibit SGLT1 activity to suppress postprandial hyperglycemia (or impaired glucose tolerance) through suppression of glucose absorption in the small intestine, whereby the compounds, for example, can suppress the onset of diabetes and metabolic syndrome or can treat these diseases. A 4-isopropylphenyl glucitol compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 represents a hydrogen atom, etc., R2 represents a methyl group, etc., R3 represents a C1-4 alkyl group substituted with an amino group(s), etc., and R4 represents a hydrogen atom, etc.
    Type: Application
    Filed: February 23, 2010
    Publication date: December 15, 2011
    Applicant: TAISHO PHARMACEUTICAL CO., LTD
    Inventors: Hiroyuki Kakinuma, Yohei Kobashi, Tomomichi Chonan, Takahiro Oi, Fumiyasu Shiozawa, Yuki Iwata, Kenichi Kawabe
  • Phenylpyrimidone Compounds, the Pharmaceutical Compositions, Preparation Methods and Uses Thereof
    Publication number: 20110301109
    Abstract: The present invention relates to a class of phenylpyrimidone compounds, the pharmaceutical composition, the preparation method and the use thereof. More specifically, the present invention relates to a type of phenylpyrimidone compounds of the following formula I, the pharmaceutically acceptable salts or solvates thereof and to the pharmaceutical composition as well as the preparation method of the compounds. The compounds of formula I according to the present invention can effectively inhibit type V phosphodiesterase (PDE5), and thus can be used for the treatment of various vascular disorders, such as male erectile dysfunction, pulmonary hypertension and the like.
    Type: Application
    Filed: December 10, 2009
    Publication date: December 8, 2011
    Applicants: TOPHARMAN SHANGHAI CO., LTD.
    Inventors: Zheng Liu, Jianfeng Li, Xiaojun Yang, Zhen Wang, Jinfeng Zhang, Yi Zhu, Guanghui Tian, Qing Jin, Jingkang Shen, Weiliang Zhu, Hualiang Jiang, Jingshan Shen
  • CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY
    Publication number: 20110301083
    Abstract: Conjugates which comprise a drug and a ligand which includes a first saccharide; wherein the conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic or pharmacodynamic property of the conjugate is sensitive to serum concentration of a second saccharide. Exemplary conjugates and sustained release formulations are provided in addition to methods of use and preparation.
    Type: Application
    Filed: January 27, 2010
    Publication date: December 8, 2011
    Inventors: Todd C. Zion, Thomas M. Lancaster
  • Polysaccharide pseudo-sponge
    Patent number: 8071756
    Abstract: A photocrosslinked polysaccharide pseudo-sponge exhibiting a low swelling property and a high degradation ability in vivo while retaining a suitable strength. The polysaccharide pseudo-sponge is produced by a crosslinking reaction of a photoreactive polysaccharide obtained by introducing a photoroactive group into a polysaccharide, and exhibits a low swelling property and a blue dextran-low dyaffinity.
    Type: Grant
    Filed: September 10, 2004
    Date of Patent: December 6, 2011
    Assignee: Seikagaku Corporation
    Inventor: Tomoya Sato
  • DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE
    Publication number: 20110294749
    Abstract: A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided. A pyrimidine derivative or a salt thereof, which has an arylamino or arylethylamino group which may be substituted with a specified substituent, at the 2-position, amino group substituted with benzyl group or the like, at the 4-position, and carbamoyl group which may be substituted, at the 5-position, is provided.
    Type: Application
    Filed: June 28, 2011
    Publication date: December 1, 2011
    Applicant: Astellas Pharma Inc.
    Inventors: Shinya Nagashima, Hiroshi Nagata, Masahiro Iwata, Masaki Yokota, Hiroyuki Moritomo, Eiichi Nakai, Sadao Kuromitsu, Keiko Ohga, Makoto Takeuchi
  • CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
    Publication number: 20110294998
    Abstract: The present invention relates to novel compositions comprising polymeric moieties covalently attached to therapeutic agents, wherein the therapeutic agent is attached to the polymeric moiety through a tether. By selecting from a variety of tether groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein.
    Type: Application
    Filed: August 4, 2011
    Publication date: December 1, 2011
    Applicant: CERULEAN PHARMA INC.
    Inventors: Mark E. Davis, Jungyeon Hwang, Tianyi Ke, Ching-Jou Lim, Thomas Schluep
  • HYDROGELS CROSSLINKED WITH GOLD NANOPARTICLES AND METHODS OF MAKING AND USING THEREOF
    Publication number: 20110280914
    Abstract: Described herein are composites useful in tissue and organ engineering. In one aspect, the composite comprises the reaction product between a macromolecule comprising at least one thiol group and a gold nanoparticle. The thiolated macro-molecule crosslinks with the gold nanoparticle to produce a composite that is useful in anchoring cells. The composites can be used to form multi-layer 3-D structures, where the cells in each layer can aggregate and fuse with one another to form tissues and organs.
    Type: Application
    Filed: December 17, 2009
    Publication date: November 17, 2011
    Applicant: University of Utah Research Foundation
    Inventors: Glenn D. Prestwich, Aleksander Skardel, Jianxing Zhang
  • LOW-MOLECULAR POLYSULFATED HYALURONIC ACID DERIVATIVE AND MEDICINE CONTAINING SAME
    Publication number: 20110281819
    Abstract: A low-molecular-weight polysulfated hyaluronic acid derivative useful for prevention and/or treatment of an allergic disease. An agent for prevention and/or treatment of an allergic disease selected from pollinosis, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, and asthma, represented by the following general formula (IA) or (IB); wherein n represents a number of 0 to 15; R?s each independently represent a hydrogen atom or an SO3H group etc.
    Type: Application
    Filed: February 1, 2010
    Publication date: November 17, 2011
    Applicants: OTSUKA PHARMACEUTICAL CO., LTD., OTSUKA CHEMICAL CO., LTD.
    Inventors: Kazuaki Kakehi, Hiroaki Asai, Naohiro Hayashi, Satoshi Shimizu, Fumitaka Goto, Yasuo Koga, Takahiro Tomoyasu, Takao Taki, Yusuke Kato, Satoru Nakazato, Junji Takaba, Atsushi Azuma, Wakako Hirano, Kazunari Izumi, Minoru Kashimoto, Yoko Sakamoto, Takashi Hayashi, Masaru Nishida
  • PRODUCTION OF HYALURONIC ACID
    Publication number: 20110281817
    Abstract: Methods for producing hyaluronic acid are described, including altering the activity in Streptococcus cells of one or more enzymes and/or altering the amount of available substrates or substrate precursors.
    Type: Application
    Filed: August 29, 2008
    Publication date: November 17, 2011
    Applicants: SUGAR INDUSTRY INNOVATION PTY. LTD., THE UNIVERSITY OF QUEENSLAND
    Inventors: Lars Keld Nielsen, Wendy Chen, Esteban Stefane Marcellin Saldana
  • METHOD FOR IDENTIFYING INHIBITORS OF LIPOTEICHOIC ACID SYNTHASE
    Publication number: 20110282028
    Abstract: The invention provides a method of identifying an inhibitor of LtaS comprising: (a) providing bacteria which comprise a mutation in the mbl gene or homologue thereof; (b) culturing the bacteria of (a) in the presence of a test substance under conditions of low magnesium; (c) monitoring the growth of the bacteria; wherein growth or more rapid growth of the bacteria compared to growth in the absence of the test substance is indicative that the test substance is an inhibitor of LtaS.
    Type: Application
    Filed: December 4, 2009
    Publication date: November 17, 2011
    Applicant: UNIVERSITY OF NEWCASTLE UPON TYNE
    Inventors: Jeffery Errington, Kathrin Schirner
  • Compounds and Combinations
    Publication number: 20110274646
    Abstract: The present invention relates to a combination of a hyaluronan oligomer and/or polymer and a factor capable of mobilizing stem cells. The present invention also relates to a method for altering the relative amounts of blood cells and/or the types of blood cells in a subject by administering the combination to the subject. Further, the present invention relates to a method for mobilizing stem cells to the bloodstream of a subject by administering the combination to the subject. Additionally, the present invention relates to a hyaluronan oligomer and/or polymer.
    Type: Application
    Filed: May 6, 2011
    Publication date: November 10, 2011
    Applicants: Glykos Finland Oy, Suomen Punainen Risti Veripalvelu
    Inventors: Johanna Nystedt, Heidi Anderson, Tero Satomaa, Jari Natunen, Jari Helin, Juhani Saarinen
  • GLUCOSIDE DERIVATIVES AND USES THEREOF
    Publication number: 20110269700
    Abstract: The present invention relates to compounds of formula I and pharmaceutically acceptable salts thereof, and to formulations and uses of the compounds of formula (I) in the treatment of metabolic disorders.
    Type: Application
    Filed: September 17, 2009
    Publication date: November 3, 2011
    Inventors: P. Venkata Palle, Debnath Bhuniya, Dumbala Srinivas Reddy, Suresh Eknath Kurhade
  • ARYL/ALKYL VINYL SULFONE HYALURONIC ACID DERIVATIVES
    Publication number: 20110257123
    Abstract: A hyaluronic acid derivative, and methods of producing and using said derivative, the derivative comprising n repeating units and having the general structural formula (I), wherein, in at least one repeating unit, one or more of R1, R2, R3, R4 comprises an etherbound aryl/alkyl sulfone having the general structural fomula (II), wherein R comprises an alkyl- or aryl-group, and otherwise R1, R2, R3, R4 are hydroxyl groups, OH.
    Type: Application
    Filed: March 2, 2007
    Publication date: October 20, 2011
    Applicant: Novozymes Biopolymer A/S
    Inventors: Corinne Eenschooten, Morten Wurtz Christensen
  • STEREOREGULAR ROMP POLYMERS
    Publication number: 20110251363
    Abstract: The invention relates to stereoregular ROMP polymers, the monomers used to make them, and the processes used to convert the monomers to the polymers.
    Type: Application
    Filed: July 17, 2007
    Publication date: October 13, 2011
    Inventors: Nicole S. Sampson, Kathlyn A. Parker
  • GLUCOSE-PEG CONJUGATES FOR REDUCING GLUCOSE TRANSPORT INTO A CELL
    Publication number: 20110243851
    Abstract: There is provided a glucose-PEG conjugate comprising a PEG moiety conjugated to a linear glucose moiety at the C1 position of the glucose moiety. The glucose-PEG conjugate may be used to reduce glucose transport into a cell and may be used to treat a proliferative disorder.
    Type: Application
    Filed: December 11, 2009
    Publication date: October 6, 2011
    Applicant: Agency for Science, Technology and Research
    Inventors: Karthikeyan Narayanan, Andrew Chwee Aun Wan, Jackie Y. Ying, Nandanan Erathodiyil
  • Adenosine Analogs and Their Use
    Publication number: 20110237529
    Abstract: The invention provides adenosine analog compounds that act at P2Y receptors, e.g., the P2Y2 receptor, including pharmaceutical compositions; and uses thereof to treat or prevent diseases associated with that receptor, e.g., disorders relating to mucus secretion, such as cystic fibrosis, chronic obstructive pulmonary disorder (COPD), asthma, constipation, chronic idiopathic constipation, dry mouth (xerostomia), gum disease, and gastrointestinal problems caused by radiation and chemotherapy for cancer.
    Type: Application
    Filed: November 16, 2007
    Publication date: September 29, 2011
    Inventors: Efrat Ben-Zeev, Vincent Jacques, Yael Marantz, A. Sekar Reddy, Zhaoda Zhang, Oren Becker, Dilara Mccauley, Pini Orbach, Sharon Shacham, Ashis K. Saha, Michael Xie
  • METHOD TO PRODUCE HYALURONIC ACID FUNCTIONALIZED DERIVATIVES AND FORMATION OF HYDROGELS THEREOF
    Publication number: 20110236486
    Abstract: A system and method are provided for controlling an internal combustion engine driving a generator/welder or a stand-alone generator. Controlling the engine may include altering the engine speed based upon a detected demand on the generator and/or operating parameters of a welder. For example, the engine speed may be increased based on a detected draw on the generator and/or the operating parameters of the welder. In addition, the engine speed may be automatically decreased to a non-standard idle speed or the engine may be automatically turned off if no demand is detected for a period of time. Additionally, the engine speed may be increased if only frequency-insensitive demands are detected on the generator. Combinations of these and further methods may be executed. Various devices are provided for implementing the above methods.
    Type: Application
    Filed: November 30, 2009
    Publication date: September 29, 2011
    Inventors: Gaetano Giammona, Fabio Palumbo, Giovanna Pitarresi
  • CHEMOSELECTIVE LIGATION
    Publication number: 20110236930
    Abstract: The present invention features a chemoselective ligation reaction that can be carried out under physiological conditions. In general, the invention involves condensation of a specifically engineered phosphine, which can provide for formation of an amide bond between the two reactive partners resulting in a final product comprising a phosphine moiety, or which can be engineered to comprise a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine byproduct and producing a native amide bond in the final product. The selectivity of the reaction and its compatibility with aqueous environments provides for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).
    Type: Application
    Filed: March 8, 2011
    Publication date: September 29, 2011
    Inventors: Eliana Saxon, Carolyn Ruth Bertozzi
  • SGLT-2 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF
    Publication number: 20110237527
    Abstract: The present invention relates to compounds which are inhibitors of sodium dependent glucose co-transporter-2 (SGLT-2). These compounds are used in the treatment of various disorders, including diabetes, impaired glucose tolerance, insulin resistance, retinopathy, nephropathy, neuropathy, cataracts, hyperglycemia, hyperinsulinemia, hyperchlolesterolemia, elevated blood level of free fatty acids or glycerol, hyperlipidemia, hypertriglyceridemia, obesity, wound healing, tissue ischemia, atherosclerosis, and hypertension. These compounds and compositions are also useful for treating and preventing kidney stones, hyperuricemia, gout, and hyponatremia. Methods of making these compounds are also described in the present invention.
    Type: Application
    Filed: March 21, 2011
    Publication date: September 29, 2011
    Applicant: ALBANY MOLECULAR RESEARCH, INC.
    Inventors: Shuang LIU, Cheng GUO, Min HU, Douglas B. KITCHEN, Peter R. GUZZO, Russell DEORAZIO
  • GLYCOSIDE DERIVATIVES AND USES THEREOF
    Publication number: 20110230403
    Abstract: The present invention relates to compounds of formula I and pharmaceutically acceptable salts, to formulations and uses of the compounds of formula (I) in the treatment of metabolic disorders.
    Type: Application
    Filed: September 17, 2009
    Publication date: September 22, 2011
    Applicant: NOVARTIS AG
    Inventors: P. Venkata Palle, Dumbala Srinivas Reddy, Suresh Eknath Kurhade, Debnath Bhuniya
  • SIALIC ACID DERIVATIVES
    Publication number: 20110224409
    Abstract: An amine or hydrazide derivative of a sialic acid unit, e.g. in a polysaccharide, is reacted with a bifunctional reagent at least one of the functionalities of which is an ester of N-hydroxy succinimide, to form an amide or hydrazide product. The product has a useful functionality, which allows it to be conjugated, for instance to proteins, drugs, drug delivery systems or the like. The process is of particular utility for derivatising amine groups introduced in sialic acid terminal groups of polysialic acids.
    Type: Application
    Filed: January 10, 2011
    Publication date: September 15, 2011
    Inventors: Sanjay JAIN, Ioannis Papaioannou, Smita Thobhani
  • Propionic Acids, Propionic Acid Esters, and Related Compounds
    Publication number: 20110224156
    Abstract: The invention relates to propionic acids, propionic acid esters, and related compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds for the treatment of various diseases or conditions, including but not limited to diseases and/or conditions of Central Nervous System (CNS).
    Type: Application
    Filed: March 8, 2011
    Publication date: September 15, 2011
    Inventors: Mark A. Wolf, Keith D. Barnes
  • MUCOACTIVE AGENTS FOR TREATING A PULMONARY DISEASE
    Publication number: 20110217339
    Abstract: The present invention relates to pharmaceutical compositions which are useful in the treatment of diseases where excess mucus is present in the respiratory tract, such as cystic fibrosis and chronic obstructive pulmonary disease. In particular, the invention relates to pharmaceutical compositions for administration by pulmonary inhalation.
    Type: Application
    Filed: March 8, 2011
    Publication date: September 8, 2011
    Applicant: Vectura Limited
    Inventors: David MORTON, David GANDERTON, John STANIFORTH, Yorick KAMLAG
  • HEXADECASACCHARIDES WITH ANTITHROMBOTIC ACTIVITY, INCLUDING A COVALENT BOND AND AN AMINO CHAIN
    Publication number: 20110212907
    Abstract: The present invention relates to novel synthetic hexadecasaccharides with antithrombotic activity, having at least one covalent bond with an amino chain, and to the preparation method thereof and to the therapeutic use thereof.
    Type: Application
    Filed: August 24, 2009
    Publication date: September 1, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Marie-Claude Rouchon, Joseph Schofield, Dave Smith, Patrick Soubayrol
  • AGENT FOR AMELIORATING BRAIN HYPOFUNCTION
    Publication number: 20110212917
    Abstract: Provided are effective and highly safe agents, medicaments and the like for ameliorating various disorders caused by brain hypofunction. Also provided is a preventing or ameliorating agent for brain hypofunction containing N-acetyl-D-mannosamine, a pharmaceutical composition for preventing, ameliorating or treating disorders due to brain hypofunction, containing an effective amount of N-acetyl-D-mannosamine and a pharmaceutically acceptable carrier, and a food comprising N-acetyl-D-mannosamine added thereto.
    Type: Application
    Filed: February 25, 2011
    Publication date: September 1, 2011
    Applicants: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kunio SHIOTA, Masayoshi KUWAHARA, Takefumi KIKUSUI, Shintaro YAGI
  • HYBRID SCFA-HYDROXYL-DERIVATIZED MONOSACCHARIDES, METHODS OF SYNTHESIS, AND METHODS OF TREATING DISORDERS
    Publication number: 20110206734
    Abstract: Described herein are fatty acid carbohydrate-hydroxyl-hybrid compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof.
    Type: Application
    Filed: August 7, 2008
    Publication date: August 25, 2011
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Kevin J. Yarema, Udayanath Aich, Christopher Thomas Campbell, Srinivasa-Gopalan Sampathkumar, Sean S. Choi, Michael Adam Meledeo, Christopher Weier
  • Disaccharides for drug discovery
    Publication number: 20110201794
    Abstract: Methods are described for the preparation of combinatorial libraries of potentially biologically active disaccharide compounds. These compounds are variously functionalized, with a view to varying lipid solubility size, function an other properties, with the particular aim of discovering novel drug or drug-like compounds, or compounds with useful properties. The invention provides intermediates, processes and synthetic strategies for the solution or solid phase synthesis of disaccharides, variously functionalized about the sugar ring, including the addition of aromaticity and charge, and the placement of pharmaceutically useful groups and isosteres.
    Type: Application
    Filed: December 17, 2010
    Publication date: August 18, 2011
    Applicant: Alchemia Limited
    Inventors: Wim Meutermans, Michael L. West, George Adamson, Giang Thanh Le, Nicholas B. Drinnan, Giovani Abbenante, Bernd Becker, Matthias Grathwohl, Premraj Rajaratnam, Gerald Tometzki
  • Hyaluronic acid derivatives
    Patent number: 7993678
    Abstract: The present invention relates to the modification of hyaluronic acid (HA) with aryl/alkyl succinic anhydrides (ASA) to produce aryl/alkyl succinic anhydride HA derivatives, to the derivatives as such, and to their applications and uses, particularly in the cosmetic and biomedical industries. The ASA-HA derivatives are expected to have interesting properties that can be used for advanced formulation (bind stronger to the skin compared to non-modified HA), possibly also in delivery systems for actives or drugs by encapsulation (nano/micro capsules) or formation of nano/micro spheres. Further, the low MW ASA-HA derivatives are expected to penetrate the skin more efficiently than non-modified HA of the same MW.
    Type: Grant
    Filed: August 26, 2006
    Date of Patent: August 9, 2011
    Assignee: Novozymes Biopolymer A/S
    Inventors: Kristoffer Tømmeraas, Corinne Eenschooten